Evergreen Wealth Solutions LLC Raises Stock Position in Johnson & Johnson $JNJ

Evergreen Wealth Solutions LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,959 shares of the company’s stock after purchasing an additional 104 shares during the quarter. Evergreen Wealth Solutions LLC’s holdings in Johnson & Johnson were worth $657,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $47,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $49,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $52,000. Finally, Capital A Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $50,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1%

JNJ opened at $179.0980 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The firm’s fifty day moving average is $163.48 and its 200 day moving average is $159.30. The stock has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Finally, Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.